Breaking News
Sort by:
Top Post
UK's Most Vulnerable People to Receive Life-saving COVID-19 Treatments in the Community
Thousands of the UK’s most vulnerable people will be among the first in the world to […]
Evusheld (Formerly AZD7442) Long-acting Antibody Combination Authorised for Emergency Use in the US for Pre-exposure Prophylaxis (Prevention) of COVID-19
AstraZeneca‘s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorisation (EUA) in the […]
Sosei Heptares Receives Grant Funding from Wellcome to Advance the Development of Potent, Differentiated Oral Anti-Viral Small Molecules to Treat COVID-19
Sosei Group Corporation (“the Company”; TSE: 4565) today announced it has received grant funding from […]
CHMP Recommends EU Approval of Actemra/RoActemra to Treat Patients with Severe COVID-19
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee […]
Roche to Launch SARS-CoV-2 & Flu A/B Rapid Antigen Test in Countries Accepting the CE Mark to Enable Rapid Differentiation of Viral Respiratory Infections
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced its plans to launch the SARS-CoV-2 & Flu […]
MHRA Approves Xevudy (sotrovimab), a COVID-19 Treatment Found to Cut Hospitalisation and Death by 79%
Another COVID-19 treatment, Xevudy (sotrovimab), has today been approved by the Medicines and Healthcare products […]
Moderna Announces Supply Agreement with the UK for Additional 60 Million Doses of Moderna’s COVID-19 Vaccine in 2022 and 2023
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today […]
Roche Has Rapidly Developed Additional Testing Options to Differentiate Mutations in the Omicron SARS-CoV-2 Variant
Roche (SIX: RO, ROG; OTCQX: RHHBY) and TIB Molbiol, a newly acquired subsidiary within the Roche […]
Acumen Diagnostics' PCR Capabilities to Tackle Omicron COVID-19 Variant
Homegrown medical technology Company, Acumen Diagnostics Pte. Ltd. (“Acumen Diagnostics” or the “Company”), a 51% […]
JOYSBIO's SARS-COV-2 Antigen Rapid Test Detects OMICRON Variant
JOYSBIO, one of the world’s leading manufacturers of lateral flow rapid tests, is proud to […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more